Business Description
Transcenta Holding Ltd
ISIN : KYG9005B1041
Total Employee Number:
155Compare
Compare
Traded in other countries / regions
06628.Hong Kong IPO Date
2021-09-29Description
Transcenta Holding Ltd is a clinical-stage biopharmaceutical company with fully integrated capabilities across discovery, research, clinical development, and manufacturing, uniquely positioned to advance high-impact biologic innovations with commercial potential. The company's asset, Osemitamab (TST001), is a anti-Claudin18.2 monoclonal antibody currently advancing toward late-stage development. It is building a differentiated pipeline spanning oncology, osteoporosis, kidney disease, and autoimmune disorders. It operates in a single segment and geographically its operations are spread across Chinese mainland, United States of America, and Others with Chinese Mainland deriving the majority of revenue.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.11 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | -0.66 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -6.19 | |||||
Beneish M-Score | -2.61 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -57.6 | |||||
3-Year EBITDA Growth Rate | 22.8 | |||||
3-Year EPS without NRI Growth Rate | 20.6 | |||||
3-Year FCF Growth Rate | 22.6 | |||||
3-Year Book Growth Rate | -25.8 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 12.54 | |||||
9-Day RSI | 23.31 | |||||
14-Day RSI | 30.39 | |||||
3-1 Month Momentum % | -19.18 | |||||
6-1 Month Momentum % | -49.14 | |||||
12-1 Month Momentum % | -79.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.25 | |||||
Quick Ratio | 0.19 | |||||
Cash Ratio | 0.07 | |||||
Days Inventory | 962.85 | |||||
Days Sales Outstanding | 698.83 | |||||
Days Payable | 4563.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.5 | |||||
Shareholder Yield % | 17.43 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 23.12 | |||||
Operating Margin % | -2457.39 | |||||
Net Margin % | -2735.02 | |||||
EBITDA Margin % | -2590.15 | |||||
FCF Margin % | -1918.99 | |||||
OCF Margin % | -1821.05 | |||||
ROE % | -30.54 | |||||
ROA % | -19.52 | |||||
ROIC % | -16.91 | |||||
3-Year ROIIC % | -42.39 | |||||
ROC (Joel Greenblatt) % | -62.02 | |||||
ROCE % | -25.81 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 47.89 | |||||
PB Ratio | 0.57 | |||||
Price-to-Tangible-Book | 7 | |||||
EV-to-EBIT | -2.65 | |||||
EV-to-EBITDA | -2.71 | |||||
EV-to-Revenue | 70.18 | |||||
EV-to-FCF | -3.66 | |||||
Price-to-GF-Value | 3.14 | |||||
Earnings Yield (Greenblatt) % | -37.74 | |||||
FCF Yield % | -40.48 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Transcenta Holding Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 8.182 | ||
| EPS (TTM) (HK$) | -0.538 | ||
| Beta | 2.4162 | ||
| 3-Year Sharpe Ratio | 0.09 | ||
| 3-Year Sortino Ratio | 0.25 | ||
| Volatility % | 66.07 | ||
| 14-Day RSI | 30.39 | ||
| 14-Day ATR (HK$) | 0.089562 | ||
| 20-Day SMA (HK$) | 1.04775 | ||
| 12-1 Month Momentum % | -79.3 | ||
| 52-Week Range (HK$) | 0.78 - 5.22 | ||
| Shares Outstanding (Mil) | 426.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Transcenta Holding Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Transcenta Holding Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-08-31 | 1.08 (-4.44%) | ||
| Second quarter earnings results for 2026 | 2026-08-31 | 1.08 (-4.44%) | ||
| General meeting for 2026 | 2026-06-30 | 1.09 (-1.80%) | ||
| Annual report for 2025 | 2026-04-28 | 2.25 (-3.85%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 2.55 (+19.16%) | ||
| 36(th) Annual Oppenheimer Healthcare Life Sciences Conference | 2026-02-26 12:00 | 2.44 (+5.63%) | ||
| Second quarter earnings results for 2025 | 2025-08-27 | 3.78 (-7.80%) | ||
| General meeting for 2025 | 2025-06-06 10:00 | 1.51 (-4.43%) | ||
| Annual report for 2024 | 2025-04-22 | 1.15 (-0.86%) | ||
| Fourth quarter earnings conference call for 2024 | 2025-03-31 18:00 | 1.82 (-3.70%) |
Show
Entries
Transcenta Holding Ltd Frequently Asked Questions
What is Transcenta Holding Ltd(HKSE:06628)'s stock price today?
The current price of HKSE:06628 is HK$0.91. The 52 week high of HKSE:06628 is HK$5.22 and 52 week low is HK$0.78.
When is next earnings date of Transcenta Holding Ltd(HKSE:06628)?
The next earnings date of Transcenta Holding Ltd(HKSE:06628) is 2027-03-30 Est..
Does Transcenta Holding Ltd(HKSE:06628) pay dividends? If so, how much?
Transcenta Holding Ltd(HKSE:06628) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers